Journal: Molecular Therapy Oncology

Article Title: Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition

doi: 10.1016/j.omton.2026.201226

Figure Lengend Snippet: Concomitant treatment with ruxolitinib protects VSV-IFNβ-NIS treated MPC-11 tumor-bearing Balb/c mice from toxicity (A) Kaplan-Meier survival, (B) individual tumor volumes, (C) predicted tumor volumes using mixed effects modeling, (D) plasma IFNβ, (E) ALT, (F) AST, and (G) platelet count of mice at scheduled bleeds on day 3 and day 14, or at necropsy (at various time points). Treatment groups are color coded, saline (black, n = 5), VSV alone (red, n = 10), ruxolitinib (gray, n = 5), and VSV plus ruxolitinib (blue, n = 10). One intravenous dose of VSV at 10 7 TCID 50 was given per mouse, and/or ruxolitinib at 2 mg twice a day by oral gavage for 10 days, starting on the same day as VSV therapy.

Article Snippet: MPC-11 murine plasmacytoma cells (CCL-167, American Type Culture Collection, Manassas, VA) were maintained in DMEM supplemented with 10% fetal bovine serum.

Techniques: Clinical Proteomics, Saline

Journal: Diabetologia

Article Title: Phenotypically distinct anti-insulin B cells repopulate pancreatic islets after anti-CD20 treatment in NOD mice

doi: 10.1007/s00125-019-04974-y

Figure Lengend Snippet: Anti-insulin B cells repopulate pancreatic islets more rapidly than insulin-negative B cells after anti-CD20 treatment. Groups of VH125.hCD20/NOD mice, aged 6–8 weeks old, were injected with 2H7 anti-CD20 or IgG isotype control. Spleen, PLNs and pancreatic islets were analysed for insulin-positive and insulin-negative B cells at 8 weeks and 12 weeks post depletion by flow cytometry. ( a – f ) No. of cells from IgG control-treated (black circles) and 2H7-treated (grey squares) mice for insulin-negative B cells ( a – c ) and insulin-positive B cells ( d – f ) from spleen ( a , d ) PLNs ( b , e ) and islets ( c , f ). ( g – i ) Percentage of B cells repopulated at 8 and 12 weeks after treatment from spleen ( g ), PLNs ( h ) and islets ( i ) of mice shown in ( a – f ). Percentages were calculated as individual numbers from each 2H7-treated mouse / mean number from all IgG control antibody-treated mice. Horizontal lines represent the median value. Data represent three independent experiments. At 8 weeks, n = 7 (spleen), n = 7 (PLNs) and n = 9 (islets) for control IgG-treated mice and n = 10 (spleen), n = 9 (PLNs) and n = 12 (islets) for 2H7-treated mice. At 12 weeks, n = 8 (spleen), n = 6 (PLNs) and n = 7 (islets) for control IgG and n = 11 (spleen), n = 7 (PLNs) and n = 11 (islets) for 2H7-treated mice. * p < 0.05 (one-way ANOVA)

Article Snippet: Female VH125.hCD20/NOD mice, 6–8 weeks of age were chosen at random to receive either anti-hCD20 antibody (clone 2H7; Bio-XCell, West Lebanon, NH, USA) or control IgG2b antibody (clone MPC-11; Bio-XCell [ , , ]), as described previously [ ].

Techniques: Injection, Control, Flow Cytometry

Journal: Diabetologia

Article Title: Phenotypically distinct anti-insulin B cells repopulate pancreatic islets after anti-CD20 treatment in NOD mice

doi: 10.1007/s00125-019-04974-y

Figure Lengend Snippet: CD138 int anti-insulin B cells are enriched in pancreatic islets after anti-CD20 treatment. Groups of 6- to 8-week-old VH125.hCD20/NOD mice were injected with 2H7 anti-CD20 or IgG isotype control. Groups of mice ( n = 2 or 3 per group) were pooled and insulin + B cells from pancreatic islets were analysed for four different populations based on CD138 expression: CD138 − (blue); CD138 int IgM + (orange); CD138 int IgM lo (grey) and CD138 hi IgM lo (red). ( a , b ) Representative flow plots showing gating on live CD3 − CD11b − CD11c − ( a ) and graph showing the overall percentages of the four different populations ( b ). ( c , d ) Representative flow plots showing insulin − CD19 + , insulin + CD19 + and insulin + CD19 − cells ( c ) and graph showing the overall percentages of these cells ( d ); 2H7 (black circles), IgG (grey circles). ( e ) Representative flow plots showing CD138 and IgM expression in insulin + CD19 + and insulin + CD19 − cells. ( f , g ) Graphs showing CD138 and IgM populations on insulin + CD19 + ( f ) and insulin + CD19 − cells ( g ) ( n = 5 groups for control IgG treatment; n = 4 groups for 2H7 treatment). Horizontal lines represent the median values. Data represent two independent experiments. * p < 0.05 (one-way ANOVA)

Article Snippet: Female VH125.hCD20/NOD mice, 6–8 weeks of age were chosen at random to receive either anti-hCD20 antibody (clone 2H7; Bio-XCell, West Lebanon, NH, USA) or control IgG2b antibody (clone MPC-11; Bio-XCell [ , , ]), as described previously [ ].

Techniques: Injection, Control, Expressing

Journal: Developmental cell

Article Title: Hedgehog Pathway Activation Requires Coreceptor-Catalyzed, Lipid-Dependent Relay of the Sonic Hedgehog Ligand

doi: 10.1016/j.devcel.2020.09.017

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Mouse: Shh-LIGHT2 , ATCC; Taipale et al., 2000 , Cat# CRL-2795; RRID: CVCL_2721.

Techniques: Virus, Recombinant, SYBR Green Assay, Purification, Luciferase, CRISPR, Sequencing, Blocking Assay, Software, Microscopy

Journal: bioRxiv

Article Title: A genetic signature predicts aggressive paraganglioma sensitivity to dual PI3K-CDK4/6 inhibition therapy

doi: 10.1101/2025.02.18.638668

Figure Lengend Snippet: (A,B) IC 50 curves of PC12 ( A ) or MPC ( B ) cells treated with CDK4/6i, PI3Ki, their combination or DMSO control. Cell proliferation was measured after 72h of treatment. For drug concentrations see Suppl. Table S1. The DMSO control was set to 100% and nonlinear regression was used to calculate the IC 50 . Data shown are the mean±SD from 3 independent experiments with 3 technical replicates each. ( C,D ) PC12 ( C ) and MPC ( D ) cells were treated using the indicated concentrations and Caspase 9 activity was measured 72h later. Shown is the relative apoptosis normalized to the DMSO control. Data shown is the mean ± SD from 3 independent experiments with 3 technical replicates each. Statistics: 2way ANOVA. ( E,F ) PC12 cells were plated in chambers without Matrigel to assess migration ( E ), or containing Matrigel to assess invasion ( F ). After 72h of treatment with IC 50 values of the drugs, chambers were collected, stained and cells counted (3 technical replicates for each condition). Data shown are the mean±SD from 3 independent experiments. Statistics: 1way ANOVA. ns, not significant; *, p< 0.05; **, p< 0.01; ***, p<0.001; ****, p< 0.0001. ( G,H ) Expression and quantification of total Akt, phospho-Akt (pAKT), total S6, phosphor-S6 and α-Tubulin (loading control) in PC12 ( G ) or MPC ( H ) cells treated with the indicated drugs for 72h. Shown is one representative immunoblot out of 3 independent experiments. Band quantification was conducted using Image J. Statistics: 1way ANOVA. ns, not significant; *, p< 0.05; **, p< 0.01; ***, p<0.001; ****, p< 0.0001. ( I,J ) Realtime qRT-PCR for Ccna and Pcna was conducted on PC12 ( I ) and MPC ( J ) cells with the various drugs/drug combination. RNA was extracted 72h post-treatment. Values were normalized against the DMSO control arbitrarily set to 1. Data are shown as the mean of three experiments ± SD. Statistics: 1way ANOVA. ns, not significant; *, p< 0.05; **, p< 0.01; ***, p<0.001; ****, p< 0.0001.

Article Snippet: PC12 cells were obtained from ATCC, while MPC cells were provided by Prof. A. Tischler (Tufts University School of Medicine).

Techniques: Control, Activity Assay, Migration, Staining, Expressing, Western Blot, Quantitative RT-PCR

Journal: bioRxiv

Article Title: A genetic signature predicts aggressive paraganglioma sensitivity to dual PI3K-CDK4/6 inhibition therapy

doi: 10.1101/2025.02.18.638668

Figure Lengend Snippet: (A, B) Following spheroid formation, PC12 ( A ) or MPC ( B ) cells were treated with different doses of CDK4/6i, PI3Ki, their combination or DMSO control. Cell viability was assessed 72h later. Reported is the relative cell viability normalized against untreated control (arbitrarily set to 1). Data shown are the mean±SD from 3 independent experiments with 8 technical replicates each. Statistics: 1way ANOVA. ns, not significant; *, p< 0.05; **, p< 0.01; ***, p<0.001; ****, p< 0.0001.( C,D ) 3D spheroids of PC12 ( C ) and MPC ( D ) cells were treated with the indicated drugs at the concentration of CDK4/6i: 8 μM; PI3Ki: 2 μM, combination: 8μM CDK4/6i + 2 μM PI3Ki. Spheroid size was measured over time and the values at the 3 Day time point are shown. Data shown are the mean ±SD from 3 independent experiments with 8 technical replicates each. Statistics: 1way ANOVA. ns, not significant; *, p< 0.05; **, p< 0.01; ***, p<0.001; ****, p< 0.0001. ( E,F) Primary cells were isolated from fresh MENX-associated PCC fragments (n=7). 3D spheroids were generated and treated with the indicated drugs at the concentrations reported in C . ( E ) Cell viability was measured 72h later and normalized against the initial measurement and the DMSO control. Data shown is the mean ±SD with 5-15 technical replicates each tumor (depending on total amount of cells). Statistics: 1way ANOVA. ns, not significant; *, p< 0.05; **, p< 0.01; ***, p<0.001; ****, p< 0.0001. ( F ) Primary cells were isolated from 3 rats, processed and treated as in E . Annexin V signal was measured 30h post-treatment to assess apoptosis. Shown is relative apoptosis normalized to the DMSO control. Data shows the mean ±SD from primary cells of 3 rats with 8 technical replicates each. Statistics: 1way ANOVA. ns, not significant; *, p< 0.05; **, p< 0.01; ***, p<0.001; ****, p< 0.0001.( G,H ) Primary cells were isolated from 8 fresh patient-derived PPGL and 3D organotypic cultures generated. Spheroids were treated with CDK4/6i (8μM), PI3Ki (2μM), their combination (CDK4/6i 8μM + PI3Ki 2 μM), or DMSO. Cell viability was measured 72h later. Shown is the relative cell viability normalized to the initial measurement and the DMSO control. In ( G ) the mean ±SD from primary cells of 8 patients with 4-8 technical replicates each (depending on total amount of cells) is shown. Statistics: 1way ANOVA. ns, not significant; *, p< 0.05; **, p< 0.01; ***, p<0.001; ****, p< 0.0001. In ( H ) the response of 6 individual patients is illustrated as the mean value.

Article Snippet: PC12 cells were obtained from ATCC, while MPC cells were provided by Prof. A. Tischler (Tufts University School of Medicine).

Techniques: Control, Concentration Assay, Isolation, Generated, Derivative Assay